Recombinant Human Interferonα2b (Shanghai Wanxing)

注射用重组人干扰素α2b(酵母)(上海万兴)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant Human Interferonα2b (Shanghai Wanxing)
Drug Alias Name万复因
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsNeoplasmsVirus Diseases
Global Approved IndicationsNeoplasmsVirus Diseases
Approved Indications in ChinaNeoplasmsVirus Diseases
Original Approved Country/TerritoryMainland China
Original Approved Date2001/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Tenry Pharmaceutical Co LtdShanghai Wanxing Biological Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Tenry Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasmsVirus Diseases
Inactive IndicationsN/A

Other Information

ATC CodeL03AB05
Related LinksN/A